Endocrine Pharmacology Practice Questions

Q: Which of the following is a long-acting corticosteroid?

Betamethasone. **Betamethasone** - **Betamethasone** is classified as a **long-acting corticosteroid** with a duration of action greater than 36 hours. - Its prolonged action is due to its chemical structure, which allows for slower metabolism and excretion. *Triamcinolone* - **Triamcinolone** is an **intermediate-acting corticosteroid** with a duration of action typically between 12 to 36 hours. - It is often used for conditions requiring an effect longer than hydrocortisone but shorter than the ultra-long acting corticosteroids. *Hydrocortisone* - **Hydrocortisone** is a **short-acting corticosteroid**, with a duration of action of 8-12 hours. - It is equivalent to the natural hormone **cortisol** and is primarily used for replacement therapy or conditions requiring a rapid, short-term effect. *Prednisolone* - **Prednisolone** is an **intermediate-acting corticosteroid**, similar to triamcinolone, with a duration of action between 12 to 36 hours [1]. - It is frequently used for inflammatory and autoimmune conditions due to its potent anti-inflammatory effects.

Q: Which of the following drugs does not cause adrenocortical suppression?

Spironolactone. ***Spironolactone*** - This drug is an **aldosterone antagonist** and a **potassium-sparing diuretic**. While it can interfere with androgen synthesis and bind to androgen and progesterone receptors, it does not directly cause generalized adrenocortical suppression of cortisol or other adrenal hormones. - Its primary actions are on the **renal tubules** to increase sodium and water excretion while retaining potassium. *Prednisone* - Prednisone is a **synthetic glucocorticoid** that, when administered exogenously, suppresses the body's natural production of cortisol by inhibiting the HPA axis (hypothalamic-pituitary-adrenal axis). - Chronic use leads to **adrenal atrophy** and decreased endogenous cortisol secretion, requiring gradual tapering to allow adrenal recovery. *Ketoconazole* - Ketoconazole is an antifungal agent that also inhibits several **cytochrome P450 enzymes** involved in steroid biosynthesis, including 11β-hydroxylase and 17α-hydroxylase. - This inhibition directly reduces the production of **cortisol** and other adrenal steroids, making it useful in conditions like Cushing's syndrome but also causing adrenocortical suppression as a side effect. *Mitotane* - Mitotane is an **adrenolytic agent** specifically used in the treatment of adrenocortical carcinoma. - It causes **selective atrophy and necrosis** of the adrenal cortex, leading to a significant reduction in cortisol and other adrenal steroid production.

Q: Which of the following actions are associated with Danazol?

All of the options. ***All of the options*** - **Danazol** is a synthetic steroid with a variety of hormonal activities, including **weak androgenic**, **anabolic**, and **progestational** effects. - Its diverse pharmacological profile contributes to its therapeutic uses, particularly in conditions like **endometriosis** and **fibrocystic breast disease**, where it suppresses gonadotropin release and ovarian function. - All three properties listed (androgenic, progestational, and anabolic) are characteristics of Danazol. **Weak androgenic activity:** - Danazol possesses **weak androgenic activity**, meaning it can bind to androgen receptors and exert effects similar to, but less potent than, testosterone. - This can lead to side effects such as **hirsutism**, **acne**, and **voice deepening** in some patients. **Progestational activity:** - While not its primary action, Danazol has some **progestational properties** due to its steroid structure, contributing to its ability to suppress the hypothalamic-pituitary-ovarian axis. - This activity helps in creating a **hypoestrogenic state**, which is beneficial in treating conditions like endometriosis. **Anabolic activity:** - Danazol has **anabolic effects**, promoting protein synthesis and muscle growth, similar to other anabolic steroids. - This property is utilized in treating **hereditary angioedema** by increasing C1 esterase inhibitor levels. - This can lead to side effects like **weight gain** and changes in **lipid profiles**.

Q: HbA1C is decreased most by?

Biguanides. ***Biguanides***- **Metformin**, the primary biguanide, is considered a first-line agent for type 2 diabetes and can significantly lower **HbA1c** by 1.0-2.0% [1].- It primarily works by decreasing hepatic **glucose production** and increasing **insulin sensitivity** in peripheral tissues [1].*Sulfonylureas*- Sulfonylureas stimulate **insulin release** from pancreatic beta cells, thereby lowering blood glucose.- They typically decrease **HbA1c** by 1.0-2.0%, similar to biguanides, but are associated with a higher risk of **hypoglycemia** and weight gain.*Thiazolidinediones*- Thiazolidinediones (TZDs) improve **insulin sensitivity** in peripheral tissues and reduce hepatic glucose production [1].- They reduce **HbA1c** by approximately 0.5-1.5% but have a slower onset of action and are associated with side effects like **fluid retention** and weight gain [1].*Acarbose*- Acarbose is an **alpha-glucosidase inhibitor** that delays the absorption of carbohydrates in the small intestine, primarily reducing postprandial glucose excursions [2].- Its effect on **HbA1c** is more modest, typically lowering it by 0.5-0.8%, making it less potent for overall long-term glucose control compared to other agents.

Q: What is the primary reason for hepatic involvement in oral contraceptives?

Estrogen. ***Estrogen*** - **Estrogen** components of oral contraceptives are primarily responsible for potential hepatic side effects, including some cases of **cholestasis** and **hepatocellular adenomas**. - High doses of estrogen can alter **liver enzyme metabolism** and affect bile flow. *Progesterone* - **Progesterone** components alone are generally not associated with significant hepatic dysfunction. - While synthetic progestins are metabolized by the liver, they typically do not induce the same level of hepatic risk as estrogen. *Estrogen + Progesterone* - While both hormones are present in combined oral contraceptives, the **estrogenic component** is the main driver of hepatic involvement. - The liver effects are primarily attributed to estrogen's influence on **hepatic synthesis** and metabolism, with progesterone playing a less direct role in adverse hepatic events. *Mixed trace elements* - **Oral contraceptives** do not contain significant amounts of mixed trace elements that would account for hepatic involvement. - Hepatic issues related to trace elements are usually associated with **toxicity** or deficiency states not relevant to oral contraceptive use.

Q: A middle-aged male patient presents with protrusion of the chin, excessive sweating, impaired glucose tolerance, and enlargement of hands and feet. Which of the following is a growth hormone receptor antagonist used to treat this condition?

Pegvisomant. ***Pegvisomant*** - **Pegvisomant** is a **growth hormone receptor antagonist** that binds to growth hormone receptors, preventing endogenous growth hormone from signaling and reducing IGF-1 levels. - It is specifically used in the treatment of **acromegaly**, a condition characterized by excessive growth hormone secretion, which aligns with the patient's symptoms of chin protrusion, excessive sweating, impaired glucose tolerance, and enlarged hands and feet. *Octreotide* - **Octreotide** is a **somatostatin analog** that works by inhibiting growth hormone secretion from the pituitary gland. - While used in acromegaly, it is not a growth hormone receptor antagonist, but rather reduces the production of growth hormone itself. *Cabergoline* - **Cabergoline** is a **dopamine agonist** primarily used to treat hyperprolactinemia by inhibiting prolactin secretion. - It can sometimes be used in acromegaly for patients with co-secretion of prolactin or those who are sensitive to its effects on growth hormone, but it is not a direct growth hormone receptor antagonist. *Olcegepant* - **Olcegepant** is a **calcitonin gene-related peptide (CGRP) receptor antagonist** developed for the treatment of migraine. - It has no known therapeutic role in the management of acromegaly or growth hormone-related disorders.

Q: Misoprostol used in the induction of labour is an analogue of which of the following type of prostaglandin?

PG E1. ***PG E1*** - **Misoprostol** is a synthetic analogue of **prostaglandin E1 (PGE1)**, which is used for cervical ripening and uterine contractions in labor induction. - PGE1 analogues help to soften the cervix, increase its compliance, and stimulate uterine smooth muscle contraction. *PG E2* - **Dinoprostone** is a synthetic analogue of **prostaglandin E2 (PGE2)**, commonly used for cervical ripening and induction of labor. - While PGE2 also induces labor, misoprostol specifically mimics the actions of PGE1. *PG I2* - **Prostacyclin (PGI2)** is primarily known for its role in inhibiting platelet aggregation and causing vasodilation. - It is not routinely used for labor induction due to its primary vascular effects and lack of direct uterine contractile properties at relevant doses. *PG F2alpha* - **Prostaglandin F2-alpha (PGF2α)**, such as **carboprost**, is used for postpartum hemorrhage to cause strong uterine contractions. - While it causes uterine contractions, its primary obstetric use is not for labor induction but rather for stimulating aggressive uterine contraction to stop bleeding.

Q: What is the first-line drug for osteoporosis in postmenopausal women?

Bisphosphonates. ***Bisphosphonates*** - **Bisphosphonates** are the **first-line treatment** for osteoporosis in postmenopausal women due to their proven efficacy in reducing the risk of fragility fractures. - They work by **inhibiting osteoclast activity**, thereby decreasing bone turnover and increasing bone mineral density. *Oral Contraceptive Pills* - **Oral contraceptive pills** are primarily used for contraception and managing menstrual irregularities; they are **not a treatment for established osteoporosis**. - While estrogen plays a role in bone health, the focus for osteoporosis treatment is on anti-resorptive or anabolic agents. *Strontium* - **Strontium ranelate** has been used in some countries for osteoporosis, but its use is **limited due to concerns about cardiovascular adverse events** and is not typically a first-line drug. - It has a dual mechanism of action, both decreasing bone resorption and increasing bone formation. *Selective Estrogen Receptor Modulator (SERM)* - **SERMs**, such as **raloxifene**, are indicated for the prevention and treatment of osteoporosis, particularly in women with a high risk of **breast cancer**, but they are **not considered first-line** for all postmenopausal women compared to bisphosphonates. - They act as estrogen agonists in bone but are antagonists in breast and uterine tissue.

Question 1

Which of the following is a long-acting corticosteroid?

Accepted Answer

Betamethasone

Answer

Triamcinolone

Answer

Hydrocortisone

Answer

Prednisolone

Question 2

Which of the following drugs does not cause adrenocortical suppression?

Accepted Answer

Spironolactone

Answer

Prednisone

Answer

Ketoconazole

Answer

Mitotane

Question 3

Which of the following actions are associated with Danazol?

Accepted Answer

All of the options

Answer

Weak androgenic

Answer

Progestational

Answer

Anabolic

Question 4

HbA1C is decreased most by?

Accepted Answer

Biguanides

Answer

Thiazolidinediones

Answer

Sulfonylureas

Answer

Acarbose

Question 5

What is a special feature of glargine insulin?

Accepted Answer

It provides a long duration of action with a smooth, peakless effect.

Answer

It is suitable for once daily administration.

Answer

It is stable at physiological pH.

Answer

It is primarily used for basal insulin control.

Question 6

What is the primary reason for hepatic involvement in oral contraceptives?

Accepted Answer

Estrogen

Answer

Progesterone

Answer

Mixed trace elements

Answer

Estrogen + Progesterone

Question 7

A female patient presents to the emergency department with severe restlessness, palpitations,    and tremors. She is a known case of bronchial asthma. On examination, the neck looks    swollen. Blood pressure is elevated, and tachycardia is noted. ECG shows atrial fibrillation.    Which of the following drugs is used for immediate management in this patient?

Accepted Answer

Esmolol

Answer

Diltiazem

Answer

Propranolol

Answer

Propylthiouracil

Question 8

A middle-aged male patient presents with protrusion of the chin, excessive sweating, impaired glucose tolerance, and enlargement of hands and feet. Which of the following is a growth hormone receptor antagonist used to treat this condition?

Accepted Answer

Pegvisomant

Answer

Olcegepant

Answer

Cabergoline

Answer

Octreotide

Question 9

Misoprostol used in the induction of labour is an analogue of which of the following type of prostaglandin?

Accepted Answer

PG E1

Answer

PG E2

Answer

PG I2

Answer

PG F2alpha

Question 10

What is the first-line drug for osteoporosis in postmenopausal women?

Accepted Answer

Bisphosphonates

Answer

Strontium

Answer

Oral Contraceptive Pills

Answer

Selective Estrogen Receptor Modulator (SERM)

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?